Apteki 36,6

As of June 30, 2013, Apteki 36,6 has 126.02M shares outstanding.

These figures are as of June 30, 2013. The price-to-sales ratio is 0.13, and the price-to-book ratio stands at -2.89.

As of June 30, 2013, Apteki 36,6 trades at an EV/EBITDA multiple of 289.32 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.91 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 289.32 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Apteki 36,6 trades at an EV/FCF ratio of 4.07, comparing the total takeover cost of the business to the cash it actually generates for all capital providers.

As of June 30, 2013, Apteki 36,6 maintains a current ratio of 0.85, meaning it holds 0.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 442.47, indicating elevated leverage, while an interest coverage ratio of 0.07 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2013, Apteki 36,6 posted a negative return on equity (ROE) of -1,190.85, meaning shareholder capital produced losses rather than profits. Return on invested capital (ROIC) comes in at 0.30 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) is negative at -6.26, reflecting losses generated across the asset base. Return on capital employed (ROCE) is negative at -6.59, pointing to unprofitable operations over the period. Inventory turnover of 3.94 indicates how many times Apteki 36,6 sells and replaces its inventory over a year, a key working capital efficiency ratio.

These figures cover the twelve months ended June 30, 2013. That works out to an effective tax rate of 25.81, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items.

As of the close on October 23, 2026, Apteki 36,6's stock has declined approximately 22.87% over the past 52 weeks. The 50-day moving average sits at 6.23, while the 200-day moving average is 6.30.

Over the twelve months ended June 30, 2013, Apteki 36,6 posted a gross margin of 34.86, reflecting its pricing power and cost economics. The operating margin of 0.32 and net profit margin of -7.29 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2013. Free cash flow yield stands at 143.97, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 16.38, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Apteki 36,6 shareholders.

Apteki 36,6's most recent stock split took place on July 31, 2020 with a 1000:1019 split ratio.

As of June 30, 2013, Apteki 36,6 has an Altman Z-Score of 0.46, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.